279 related articles for article (PubMed ID: 24291856)
1. [Evidence of novel oral anticoagulants (NOAC)].
Kitazono T
Rinsho Shinkeigaku; 2013; 53(11):992-3. PubMed ID: 24291856
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
3. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
4. [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Kovács T
Orv Hetil; 2014 Oct; 155(42):1655-60. PubMed ID: 25305723
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Harrington AR; Armstrong EP; Nolan PE; Malone DC
Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
8. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2012; 15(4):776-85. PubMed ID: 22449118
[TBL] [Abstract][Full Text] [Related]
9. [Stroke prevention in atrial fibrillation : old and new anticoagulants].
Darius H; Sommer S
Herz; 2013 May; 38(3):231-8. PubMed ID: 23632424
[TBL] [Abstract][Full Text] [Related]
10. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
11. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
[TBL] [Abstract][Full Text] [Related]
12. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Pengo V; Crippa L; Falanga A; Finazzi G; Marongiu F; Moia M; Palareti G; Poli D; Testa S; Tiraferri E; Tosetto A; Tripodi A; Siragusa S; Manotti C
J Thromb Haemost; 2012 Oct; 10(10):1979-87. PubMed ID: 22827490
[TBL] [Abstract][Full Text] [Related]
13. Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Ezekowitz MD; Spahr J; Ghosh P; Corelli K
J Interv Card Electrophysiol; 2014 Sep; 40(3):261-8. PubMed ID: 24880227
[TBL] [Abstract][Full Text] [Related]
14. Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Destephan C; Waller AH; Patel RJ; Dhruvakumar S; Mazza V; Gerula C; Maher J; Kaluski E
Minerva Cardioangiol; 2012 Aug; 60(4):425-31. PubMed ID: 22858920
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Verdecchia P; Angeli F; Lip GY; Reboldi G
PLoS One; 2014; 9(6):e100478. PubMed ID: 24955573
[TBL] [Abstract][Full Text] [Related]
16. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
18. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Contractor T; Levin V; Martinez MW; Marchlinski FE
Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
[TBL] [Abstract][Full Text] [Related]
19. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]